A nomenclature system for the isoprostanes

被引:165
作者
Taber, DF
Morrow, JD
Roberts, LJ
机构
[1] VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232
[2] UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716
[3] VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232
来源
PROSTAGLANDINS | 1997年 / 53卷 / 02期
关键词
isoprostanes; nomenclature;
D O I
10.1016/S0090-6980(97)00005-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In 1990, prostaglandin (PG) F-2-like compounds were discovered to be produced in abundance in vivo by a free radical mechanism independent of the cyclooxygenase enzyme. Because these compounds are isomeric to cyclooxygenase-derived PGF(2 alpha), they were termed F-2-isoprostanes (F-2-IsoP's). Subsequently, it was also demonstrated that PGD(2)-like compounds (D-2-IsoP's) and PGE(2)-like compounds (E(2)-IsoP's) are also produced in vivo as products of this pathway. Four different regioisomers of each of these classes of IsoP's are formed, each of which can be comprised of eight racemic diastereomers. Thus, 64 different F-2-IsoP's, E(2)-IsoP's, and D-2-IsoP's can be formed. Interest in these molecules stems not only from the fact that quantification of IsoP's can provide a valuable index of free radical-induced lipid peroxidation in vivo but also from the fact that it has bean shown that these compounds are capable of exerting potent biological activity. Because of this potential for exerting biological activity, the chemical syntheses of various IsoP compounds for biological testing has been initiated. As a result, a need for a systematic nomenclature for these compounds has evolved. A facile nomenclature that will allow rational differentiation and designation of each of the isomeric structures comprising the family of IsoP's is presented. (C) 1997 by Elsevier Science Inc.
引用
收藏
页码:63 / 67
页数:5
相关论文
共 11 条